Nov 12, 2010 (BUSINESS WIRE) -- Guided Therapeutics, Inc. (OTCBB and QTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The company's first product, the LightTouch(TM), is a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the LightTouch was able to detect cervical cancer up to two years earlier than conventional modalities. LightTouch is designed to provide an objective result at the point-of-care, thereby improving the management of cervical disease. Guided Therapeutics has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett's Esophagus using the LightTouch technology platform. For more information, visit: www.guidedinc.com.
Company: Guided Therapeutics, Inc. Headquarters Address: 5835 Peachtree Corners East Suite D Norcross, GA 30092 Main Telephone: 770-242-8723 Website: www.guidedinc.com Ticker/ISIN: gthp(OTCBB)/US40171F1057 Type of Organization: Public IRPR Industry: Medical Devices Key Executives: CEO: Mark Faupel Investor Relations Bill Wells Contact: 770-242-8723 Phone: email@example.com Email: SOURCE: Guided Therapeutics, Inc.
Copyright Business Wire 2010 -0- KEYWORD: United States
Georgia INDUSTRY KEYWORD: Health